Hepatitis B virus vaccination for older adults

Journal of the American Geriatrics Society

Volumn 44, Issue 6, 1996, Pages 699-703

  Bennett, Richard G ^a,c   Powers, Douglas C ^a   Remsburg, Robin E ^a   Scheve, Ann ^a   Clements, Mary Lou ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS INFECTION;

EID: 0029971884     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1996.tb01835.x     Document Type: Article

References (18)

1. Cases of notifiable diseases, United States 1994. MMWR 1994;43:53.
2. McQuillan GM, Townsend TR, Fields HA et al. Seroepidemiology of hepatitis B virus infection in the United States: 1976 to 1980. Am J Med 1989;87(suppl):5S-10.
3. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: Infection or immunization? Am J Epidemiol 1982;115:26-39.
4. Occupational exposure to bloodborne pathogens: Final rule Department of Labor, Occupational Safety and Health Administration. Fed Regist 1991;56:64175-64182.
5. Wainwright RB, McMahon BJ, Bulkow LR et al. Duration of immunogencity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-2366.
6. Cook JM, Gualde N, Hessel L et al. Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol 1987;109:89-96.
7. Denis F, Mouhier M, Hessel L, et al. Hepatitis-B vaccination in the elderly. J Infect Dis 1984;149:1019.
8. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833-841.
9. Francis DP, Hadler SC, Thompson SE et al. The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982;97:362-366.
10. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-2934.
11. Wood RC, MacDonald KL, White KE et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:1935-2939.
12. Eddleston A. Modern vaccines - Hepatitis. Lancet 1990:335:1142-1145.
13. Milich DR, McNamara MK, McLachlan A et al. Distinct H2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci U S A 1985;82:8168-8172.
14. Milich DR, Thornton GB, Neurath AR et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985;228:1195-1199.
15. Miskovsky E, Gershman K, Clements ML et al. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2+S antigens. Vaccine 1991;9:346-350.
16. Clements ML, Miskovsky E, Davidson M et al. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2+S antigens. J Infect Dis 1994;170:510-516.
17. Snedecor GW, Cochran WG. Statistical Methods, 7th Ed. Ames, IA: The Iowa State University Press, 1980.
18. Horowitz MM, Ershler WB, McKinney WP, Battiolla RJ. Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine. Ann Intern Med 1988;108:185-189.